M&A and equity raisings
6,065 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
US deals dated after 30 September 2026 are still being collected.
124 deals · US$156bndisclosed · Biotech · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Oct 2026 | mAbxience | – | Fresenius | Acquisition | Completed | 1,946.9 | Biotech+1 | Lazard (buy-side) |
| Sep 2026 | Marea Therapeutics | – | Lisata Therapeutics | Acquisition | Announced | – | Biotech+1 | Goodwin (sell-side) |
| Sep 2026 | Aethlon Medical | – | – | Merger | Announced | – | Biotech | Gibson DunnMaxim GroupProcopio, Cory, Hargreaves & SavitchWedbush Securities |
| Sep 2026 | Santersus AG | – | Xenetic Biosciences | Acquisition | Announced | – | Medtech+1 | Mintz (sell-side)Lex Futura (sell-side)Holland & Knight (buy-side)Canaccord Genuity (buy-side) |
| Sep 2026 | RIGImmune | – | Leyden Labs | Acquisition | Completed | – | Biotech+1 | Gunderson Dettmer (sell-side) |
| Sep 2026 | Organica UK | – | – | Merger | Announced | – | Chemicals+2 | Brown Rudnick |
| Sep 2026 | Polaris | Demea Agro | Motion Equity Partners | Acquisition | Announced | – | Food Ingredients+2 | Goodwin (sell-side) |
| Sep 2026 | trispecific T cell-engager (TCE) asset | Chimagen Biosciences | GSK | Asset sale | Announced | 750.0 | Biotech+2 | Cooley (sell-side)Latham & Watkins (buy-side) |
| Sep 2026 | Cellipont Bioservices | – | – | Merger | Completed | – | Pharma Services+2 | William Blair |
| Sep 2026 | Orbis Medicines | – | Novo Nordisk | Stake | Announced | – | Biotech+1 | Latham & Watkins (buy-side) |
| Aug 2026 | Merida Biosciences | – | Eli Lilly and Company | Acquisition | Announced | 2,875.0 | Biotech+1 | Goodwin (sell-side)Centerview Partners (sell-side)Ropes & Gray (buy-side) |
| Aug 2026 | Ambros Therapeutics | – | Werewolf Therapeutics | Merger | Announced | 500.0 | Biotech+2 | Sidley Austin (buy-side)Cooley (sell-side)Piper Sandler (buy-side) |
| Aug 2026 | Alesta Therapeutics | – | BioMarin Pharmaceutical | Acquisition | Announced | 275.0 | Biotech+2 | J.P. Morgan (sell-side)Goodwin (sell-side)NautaDutilh (sell-side)Morgan Stanley (buy-side)Jones Day (buy-side) |
| Aug 2026 | Slate Medicines | – | Fulcrum Therapeutics | Merger | Announced | – | Biotech+1 | Goodwin (buy-side)Cooley (sell-side)Wedbush Securities (sell-side)Leerink Partners (buy-side) |
| Aug 2026 | Redx Pharma | – | Skye Bioscience | Acquisition | Announced | – | Biotech+1 | Wedbush Securities (sell-side)Cooley (sell-side)Stifel (buy-side)Morrison & Foerster (buy-side) |
| Aug 2026 | Actio Biosciences | – | Jazz Pharmaceuticals | Acquisition | Announced | 820.0 | Biotech+2 | J.P. Morgan (sell-side)Centerview Partners (sell-side)Cooley (sell-side)Moelis & Company (buy-side)Hogan Lovells Cadwalader (buy-side) |
| Aug 2026 | assets, business operations and customer relationships | – | NueCell Bio | Asset sale | Announced | – | Pharma Services+1 | Goodwin (buy-side) |
| Aug 2026 | Cy Biopharma | – | Ensysce Biosciences | Acquisition | Completed | – | Biotech+1 | H.C. Wainwright & Co.Orrick (sell-side)Wedbush Securities (sell-side)Troutman Pepper Locke (buy-side)Tungsten Advisors (buy-side) |
| Aug 2026 | Alkeus Pharmaceuticals | – | Tarsus Pharmaceuticals | Acquisition | Announced | 450.0 | Biotech+2 | Jefferies (sell-side)Latham & Watkins (sell-side)Barclays (buy-side)Gunderson Dettmer (buy-side) |
| Aug 2026 | MIMETAS | – | BRUKER | Acquisition | Completed | – | Life Sciences+1 | Raymond James |
| Jul 2026 | Neurimmune's royalty interest in AstraZeneca's cliramitug | Neurimmune | Royalty Pharma | Asset sale | Announced | 250.0 | Pharma+1 | Goodwin (buy-side) |
| Jul 2026 | Synlogic | – | – | Merger | Announced | – | Biotech+1 | Lucid Capital Markets (sell-side)Mintz (sell-side)Fenwick & West (buy-side) |
| Jul 2026 | Vidya Therapeutics | – | Processa Pharmaceuticals | Acquisition | Completed | – | Biotech+1 | Leerink Partners (sell-side)Cooley (sell-side)Tungsten Advisors (buy-side)Katten Muchin Rosenman (buy-side) |
| Jul 2026 | Forte Biosciences | – | argenx SE | Acquisition | Announced | 2,200.0 | Biotech+1 | Guggenheim Securities (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)Goldman Sachs (buy-side)Freshfields (buy-side)Innisfree M&A (buy-side) |
| Jul 2026 | OHB Pediatrics Ltd. d/b/a Oak Hill Bio | – | Research Alliance Corporation III | Merger | Announced | – | Biotech+2 | Goodwin (sell-side)Leerink Partners (buy-side)Cooley (buy-side) |
| Jul 2026 | Neuphoria Therapeutics | – | Scancell Holdings | Acquisition | Announced | – | Biotech+1 | H.C. Wainwright & Co. (sell-side)WG Partners (sell-side)Winston Taylor (sell-side)Leerink Partners (buy-side)Cooley (buy-side) |
| Jul 2026 | BioLife Solutions | – | Repligen | Acquisition | Announced | 1,500.0 | Life Sciences+1 | Centerview Partners (sell-side)K&L Gates (sell-side)Goodwin (buy-side)Perella Weinberg Partners (buy-side)Goldman Sachs (buy-side) |
| Jul 2026 | Avere Therapeutics | – | Hansoh Pharmaceutical Group Co. | Stake | Announced | – | Biotech+2 | Goodwin (buy-side) |
| Jul 2026 | AtaiBeckley | – | Eli Lilly and Company | Acquisition | Announced | 2,800.0 | Biotech+2 | Moelis & Company (sell-side)Centerview Partners (sell-side)Latham & Watkins (sell-side)Citi (sell-side)Cooley (sell-side)Sullivan & Cromwell (sell-side)Goldman Sachs (buy-side)Ropes & Gray (buy-side) |
| Jul 2026 | Kira Pharmaceuticals | – | Jasper Therapeutics | Acquisition | Completed | – | Biotech+1 | Piper Sandler (sell-side)DLA Piper (sell-side)H.C. Wainwright & Co. (buy-side)Paul Hastings (buy-side) |
| Jul 2026 | Senti Holdings, Inc. (Midco) | Senti Biosciences Holdings | Celadon Partners SPV 35 | Acquisition | Announced | – | Biotech+2 | Lincoln International (sell-side)Gunderson Dettmer (sell-side)McDermott Will & Schulte (buy-side) |
| Jul 2026 | Avere Therapeutics | – | NextCure | Merger | Announced | – | Biotech+1 | Sullivan & CromwellSidley Austin (buy-side)Gibson Dunn (sell-side)Wedbush Securities (sell-side)Tungsten Advisors (buy-side) |
| Jul 2026 | iRenix Medical | – | Tarsus Pharmaceuticals | Acquisition | Announced | 75.0 | Ophthalmology+2 | Piper Sandler (sell-side)DLA Piper (sell-side)Gunderson Dettmer (buy-side) |
| Jul 2026 | Memo Therapeutics | – | Ipsen | Acquisition | Announced | 231.1 | Biotech | Goodwin (sell-side)Centerview Partners (sell-side) |
| Jul 2026 | Myricx Bio | – | Novartis | Acquisition | Announced | 1,100.0 | Biotech+1 | Goodwin (sell-side) |
| Jul 2026 | Crinetics Pharmaceuticals | – | Vertex Pharmaceuticals | Acquisition | Announced | 10,000.0 | Biotech+2 | Lazard (buy-side)J.P. Morgan (sell-side)Leerink Partners (sell-side)Paul, Weiss (sell-side)Morrison & Foerster (sell-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side) |
| Jul 2026 | BridgeBio | – | Sixth Street | Stake | Completed | 1,000.0 | Biotech+1 | Sullivan & Cromwell (buy-side)Evercore (buy-side) |
| Jul 2026 | Kestrel | – | AbbVie | Acquisition | Announced | – | Biotech | Lazard |
| Jul 2026 | MTX652 | Mission Therapeutics | Dimerix | Asset sale | Announced | 292.0 | Biotech+1 | Guggenheim Securities (sell-side) |
| Jul 2026 | MeiraGTx Holdings | – | Oberland Capital Management | Stake | Announced | – | Biotech+1 | Latham & Watkins (sell-side) |
| Jun 2026 | Kartos Therapeutics | – | Ipsen | Acquisition | Announced | 450.0 | Biotech+1 | Goldman Sachs (sell-side)PJT Partners (sell-side)DLA Piper (sell-side)Orrick (buy-side) |
| Jun 2026 | Talawar Therapeutics | – | JATT II Acquisition Corp | Merger | Announced | – | Biotech+1 | Cooley (sell-side)Greenberg Traurig (buy-side) |
| Jun 2026 | Theravance Biopharma | – | Zymeworks | Acquisition | Pending | 929.0 | Pharma+1 | Lazard (sell-side)Evercore (sell-side)Skadden, Arps, Slate, Meagher & Flom (sell-side)Arthur Cox (sell-side)Kirkland & Ellis (buy-side)Matheson (buy-side)MTS Health Partners (buy-side) |
| Jun 2026 | Remix Therapeutics | – | Passage Bio | Merger | Pending | – | Biotech+2 | Wedbush SecuritiesRBC Capital MarketsCanaccord GenuityLatham & Watkins (sell-side)Fenwick & West (buy-side) |
| Jun 2026 | Serapha Bio | – | Boundless Bio | Merger | Pending | – | Biotech+1 | Wedbush Securities (sell-side)Gibson Dunn (sell-side)Goodwin (sell-side)Lucid Capital Markets (buy-side)Latham & Watkins (buy-side) |
| Jun 2026 | Sangamo Therapeutics capsid delivery, zinc finger, modular integrase platforms and prion disease program | Sangamo Therapeutics | Eli Lilly and Company | Asset sale | Completed | – | Biotech+1 | Raymond JamesPaul, Weiss (buy-side) |
| Jun 2026 | Apogee Therapeutics | – | AbbVie | Acquisition | Pending | 10,900.0 | Biotech+2 | Goldman Sachs (sell-side)Jefferies (sell-side)Kirkland & Ellis (sell-side)Paul, Weiss (buy-side)Morgan Stanley (buy-side) |
| Jun 2026 | 4E Therapeutics | – | Eli Lilly and Company | Acquisition | Completed | – | Biotech+1 | Wilson Sonsini Goodrich & Rosati (sell-side) |
| Jun 2026 | Azora Therapeutics | – | Adial Pharmaceuticals | Asset sale | Completed | – | Biotech+2 | Lucid Capital Markets (sell-side)Honigman (sell-side)Oppenheimer & Co. (buy-side)Blank Rome (buy-side) |
| Jun 2026 | Nuvalent | – | GSK | Acquisition | Pending | 10,600.0 | Biotech+2 | Sullivan & CromwellCenterview Partners (sell-side)Ropes & Gray (sell-side)Jefferies (sell-side)Sidley Austin (sell-side)Leerink Partners (buy-side)Citi (buy-side)Davis Polk (buy-side)Slaughter and May (buy-side)Innisfree M&A (buy-side) |
Deals come from stock exchange announcements and filings, takeover and scheme documents, prospectuses, the advisers' own deal announcements and the press. How the data is built All countries counts every deal, wherever it is, including deals whose geography is not known.Country pages cover Australia, New Zealand and the United States. The United Kingdom, Canada, Singapore, China and India are planned.